Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Heteroaromatic sulfonamide prodrugs

A technology of sulfonamide and heteroaromatic group is applied in the application field of preparing these prodrugs and preparing oral medicines, and can solve the problems of not providing active compounds, reducing metabolism and the like

Inactive Publication Date: 2008-12-10
BAYER SCHERING PHARMA OY
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Disadvantageously, although use of this formulation was shown to reduce metabolic effects, it did not provide therapeutically relevant levels of the active compound

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heteroaromatic sulfonamide prodrugs
  • Heteroaromatic sulfonamide prodrugs
  • Heteroaromatic sulfonamide prodrugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] Example 1: 3-tert-butyldimethylsilyloxyestra-1,3,5(10)-trien-17β-yl 6'-sulfamo acyl nicotinate

[0080] Under argon, 0.5 g of 3-tert-butyldimethylsilyloxyestra-1,3,5(10)-trien-17β-ol and 0.5 g of 6-sulfamoylnicotinic acid were dissolved in 7ml of pyridine. Then 0.1 g of p-Tos-OH was added and finally 0.5 g of DCC was added at 0°C. After 48 hours, the reaction mixture was stirred at room temperature. For work-up, 40 ml of water were added and the mixture was adjusted to pH~6 with 10% strength HCl. The precipitated material was filtered off, washed with water and dried. Purification by chromatography on silica gel affords 3-tert-butyldimethyl-silyloxyestra-1,3,5(10)-trien-17β-yl 6'-sulfamoyl-nicotinate .

[0081] 1 H-NMR (DMSO-d 6 ): 0.16(s, 6H, SiMe), 0.938(s, 9H, t-Bu), 0.944(s, 3H, 18-Me), 4.90(t, 1H, 17-H), 6.50-7.15(3m, 3H, CH Ar ), 7.69 (s, 2H, NH 2 ), 8.06, 8.55, 9.16 (3m, 3H, CH Py ).

Embodiment 2

[0082] Example 2: 3-Hydroxyestro-1,3,5(10)-trien-17β-yl 6'-sulfamoyl-nicotinate (1)

[0083] 300 mg of 3-tert-butyldimethylsilyloxyestra-1,3,5(10)-trien-17β-yl 6'-sulfamoylnicotinate was dissolved in 20 ml of THF. 250 mg of TBAF were added with stirring at room temperature. After 1 hour, 20 ml of water were added with stirring. This material was extracted with ethyl acetate. The organic phase was washed with saturated NaCl solution in MgSO 4 Drying, filtration, concentration and chromatographic purification on silica gel affords 3-hydroxyestra-1,3,5(10)-trien-17β-yl 6'-sulfamoyl nicotinate.

[0084] 1 H-NMR (DMSO-d 6 ): 0.94 (s, 3H, 18-Me), 4.90 (t, 1H, 17-H), 6.40-7.15 (3m, 3H, CH Ar ), 7.69 (s, 2H, NH 2 ); 8.06, 8.55 (2m, 2H, CH Py ), 9.02 (s, 1H, 3-OH), 9.17 (1s, 1H, CH Py ).

Embodiment 3

[0085] Example 3: 3-tert-butyldimethylsilyloxyestra-1,3,5(10)-trien-17β-yl 5'-sulfamo acyl nicotinate

[0086] Under argon, 0.55 g of 3-tert-butyldimethylsilyloxyest-1,3,5(10)-trien-17β-ol and 0.55 g of 5-sulfamoylnicotinic acid were dissolved in 7ml of pyridine. Then 0.12 g of p-Tos-OH were added and finally 0.55 g of DCC were added at 0°C. After 48 hours, the reaction mixture was stirred at room temperature. For work-up, 40 ml of water were added and the mixture was adjusted to pH~6 with 10% strength HCl. The precipitated material was filtered off, washed with water and dried. Chromatographic purification on silica gel yields 3-tert-butyldimethyl-silyloxyestra-1,3,5(10)-trien-17β-yl 5'-sulfamoyl-nicotinate .

[0087] 1 H-NMR (DMSO-d 6 ): 0.16(s, 6H, SiMe), 0.94(s, 9H, t-Bu), 0.95(s, 3H, 18-Me), 4.92(t, 1H, 17-H), 6.5-7.2(3m, 3H, CH Ar ), 7.79 (s, 2H, NH 2 ), 8.6-9.3 (3m, 3H, CH Py ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the sulfonamide prodrugs of formula (I), comprising a heteroaromatic linker, to a method for producing the same, to pharmaceutical compositions containing said compounds and to their use for producing orally available drugs. The compounds according to the invention bind to carboanhydrases and inhibit these enzymes.

Description

technical field [0001] The present invention relates to sulfonamide prodrugs of general formula (I): [0002] [0003] wherein X is heteroaromatic. The invention also relates to processes for the preparation of these prodrugs, pharmaceutical compositions comprising these compounds, and their use in the preparation of oral medicaments. Background technique [0004] WO 01 / 91797 discloses through the group -SO 2 NR 1 R 2 Steroids that bind to and accumulate in red blood cells. The concentration ratio of these compounds between erythrocytes and plasma is 10-1000:1, preferably 30-1000:1, thus we can be called long-acting preparations in erythrocytes. Because of the strong binding of these compounds to erythrocytes, metabolic effects during hepatic passage are avoided. Disadvantageously, although the use of this formulation was shown to reduce metabolic effects, it did not provide therapeutically relevant levels of the active compound. The reasons for this are believed t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/565A61K31/5685A61P15/02A61P15/08A61P35/00A61P43/00
CPCA61K31/565A61K31/5685A61K31/59C07J33/00C07J43/00A61P15/00A61P15/02A61P15/08A61P15/18A61P29/00A61P35/00A61P37/08A61P43/00A61P5/00A61K31/64
Inventor R·维尔瓦R·努比迈尔
Owner BAYER SCHERING PHARMA OY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com